Key takeaways
Xywav (calcium oxybate / magnesium oxybate / potassium oxybate / sodium oxybate) and sodium oxybate (Xyrem, Lumryz) are both used to treat cataplexy and excessive daytime sleepiness (EDS) in people with narcolepsy. Xywav also treats idiopathic hypersomnia (IH) in adults, which sodium oxybate does not. Xywav contains 92% less sodium than sodium oxybate, making it a better option for those needing a low-sodium diet. Sodium oxybate is available in both immediate-release and extended-release forms, while Xywav is only available as an immediate-release liquid. Both medications are controlled substances with risks of misuse and dependence, and they require enrollment in a REMS program for safe use. Common side effects for both include nausea, dizziness, and bedwetting, especially in children.
